The cardiovascular safety of antihyperglycemic agents has come under increaesed scrutiny in the last decade with the FDA now requiring manufacturers of newer classes (eg, sodium-glucose-contranposrter-2 [SGLT2] inhibitors) conduct cardiovascular outcome studies as a condition of agency approval. Studies presented at the American Diabetes Association 77th Scientific Sessions last week examined cardiovascular risk profiles of the thiazolidinedione pioglitazone and the SGLT2 inhibitor canagliflozin as well as the 3 gliflozins that make up the SGLT2 inhibitor class.
Trade names for generic drugs mentioned in this slide show appear below:
Canagliflozin (Invokana, Janssen)
Dapagliflozin (Farxiga, AstraZeneca)
Empagliflozin (Jardiance, Lilly)
Pioglitazone (Actos, Takeda Pharmaceuticals)